65,437 trials
Migraine · Tension-type Headache · Primary Headache Disorder
Primary: Numerical Rating Scale — 4.1; 4.3 units on a scale
Low Bone Mass · Low Bone Mineral Density · Males With Osteoporosis
Primary: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 — 0.9; 5.7 Percent — p=<0.0001
Acute Coronary Syndrome · Chest Pain
Primary: The Composite of Revascularization, Re-hospitalization, and Recurrent Cardiac Testing Through 90 Days. — 7; 20 participants
Type 1 Diabetes Mellitus
Primary: Measurement of the Effectiveness of APD and FMPD/APD Intervention in Adapting to Reduced Insulin Sensitivity — 176; 195 mg/dl
Acute Lymphoblastic Leukemia (ALL)
Primary: Complete Remission Plus Complete Remission Without Full Platelet Recovery (CR + CRi) — 13 participants
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Progression-free Survival — 25 months
Pain
Primary: The Percentage of Participants Who Selected Naproxen Sodium ER and Expected Their Pain to Last More Than 12 Hours — 72.0 Percentage of participants
Cystoscopes · Baxter Anaesthesia Brand of Desflurane · Sevoflurane
Primary: Recovery Time — 9; 20 Minutes
Japanese Encephalitis
Primary: SCR (Seroconversion Rate)of IC51 Compared to JE-VAX at Day 56 — 96.4; 93.6 percentage of participants
Advanced Breast Cancer
Primary: Progression Free Survival — 223; 112 Days
Carcinoma, Renal Cell
Primary: Objective Tumor Response — 31.3 Percentage of participants
Lung Cancer
Primary: Number of Patients Maintaining Stable Disease or Objective Response 2 Months After Randomization — 0; 0; 27; 7 participants — p=0.005
Colorectal Cancer
Primary: Progression Free Survival — 9.9; 10.3 Months
Social Phobia
Primary: Change From Baseline in Social Interaction Anxiety Scale (SIAS) — 43.13; 48.94; 34.85; 33.35 units on a scale — p=<0.05
Glioma
Primary: Extent of Resection — 24; 25 participants